[1] |
Acosta-Jamett G, Hernández FA, Castro N, et al. Prevalence rate and risk factors of human cystic echinococcosis: a cross-sectional, community-based, abdominal ultrasound study in rural and urban north-central Chile[J]. PLoS Negl Trop Dis, 2022, 16(3): e0010280.
doi: 10.1371/journal.pntd.0010280
|
[2] |
Wang LY, Qin M, Liu ZH, et al. Prevalence and spatial distribution characteristics of human echinococcosis in China[J]. PLoS Negl Trop Dis, 2021, 15(12): e0009996.
doi: 10.1371/journal.pntd.0009996
|
[3] |
Xu K, Wang ZX, Fan HN, et al. Hepatic echinococcosis misdiagnosed as liver cancer: a case report[J]. Chin J ParasitolParasit Dis, 2021, 39(3) :717-719. (in Chinese)
|
|
(徐凯, 王志鑫, 樊海宁, 等. 肝棘球蚴病误诊肝癌1例报告[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(3): 717-719.)
|
[4] |
Kalifu B, Meng Y, Maimaitinijiati Y, et al. Radical resection of hepatic polycystic echinococcosis complicated with hepatocellular carcinoma: a case report[J]. World J Clin Cases, 2021, 9(3): 659-665.
doi: 10.12998/wjcc.v9.i3.659
pmid: 33553405
|
[5] |
(Kazuaki, Ohtsubo. Glycosylation in cellular mechanisms of health and disease[J]. Cell, 2006, 126(5): 855-867.
doi: 10.1016/j.cell.2006.08.019
pmid: 16959566
|
[6] |
Rudd PM, Elliott T, Cresswell P, et al. Glycosylation and the immune system[J]. Science, 2001, 291(5512): 2370-2376.
doi: 10.1126/science.291.5512.2370
pmid: 11269318
|
[7] |
Bagdonaite I, Wandall HH. Global aspects of viral glycosylation[J]. Glycobiology, 2018, 28(7): 443-467.
doi: 10.1093/glycob/cwy021
pmid: 29579213
|
[8] |
Narimatsu Y, Büll C, Chen YH, et al. Genetic glycoengineering in mammalian cells[J]. J Biol Chem, 2021, 296: 100448.
doi: 10.1016/j.jbc.2021.100448
|
[9] |
Liu D, Li QH, Zhang XY, et al. Systematic review: immunoglobulin G N-glycans as next-generation diagnostic biomarkers for common chronic diseases[J]. OMICS, 2019, 23(12): 607-614.
doi: 10.1089/omi.2019.0032
pmid: 31414971
|
[10] |
Pincetic A, Bournazos S, Dilillo DJ, et al. Type I and type II Fc receptors regulate innate and adaptive immunity[J]. Nat Immunol, 2014, 15(8): 707-716.
doi: 10.1038/ni.2939
pmid: 25045879
|
[11] |
Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?[J]. Nat Rev Immunol, 2013, 13(3): 176-189.
doi: 10.1038/nri3401
pmid: 23411799
|
[12] |
Thomas D, Rathinavel AK, Radhakrishnan P. Altered glycosylation in cancer: a promising target for biomarkers and therapeutics[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(1): 188464.
doi: 10.1016/j.bbcan.2020.188464
|
[13] |
Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications[J]. Nat Rev Cancer, 2015, 15(9): 540-555.
doi: 10.1038/nrc3982
pmid: 26289314
|
[14] |
Plomp R, Bondt A, de Haan N, et al. Recent advances in clinical glycoproteomics of immunoglobulins[J]. Mol Cell Proteomics, 2016, 15(7): 2217-2228.
doi: 10.1074/mcp.O116.058503
|
[15] |
Qin WJ, Pei H, Qin RH, et al. Alteration of serum IgG galactosylation as a potential biomarker for diagnosis of neuroblastoma[J]. J Cancer, 2018, 9(5): 906-913.
doi: 10.7150/jca.22014
pmid: 29581769
|
[16] |
Harvey DJ. Electrospray mass spectrometry and fragmentation of N-linked carbohydrates derivatized at the reducing terminus[J]. J Am Soc Mass Spectrom, 2000, 11(10): 900-915.
doi: 10.1016/S1044-0305(00)00156-2
|
[17] |
Keser T, Pavić T, Lauc G, et al. Comparison of 2-aminobenzamide, procainamide and RapiFluor-MS as derivatizing agents for high-throughput HILIC-UPLC-FLR-MS N-glycan analysis[J]. Front Chem, 2018, 6: 324.
doi: 10.3389/fchem.2018.00324
pmid: 30094234
|
[18] |
Varki NM, Varki A. Diversity in cell surface sialic acid presentations: implications for biology and disease[J]. Lab Invest, 2007, 87(9): 851-857.
doi: 10.1038/labinvest.3700656
pmid: 17632542
|
[19] |
Zhang Y, Wang RH, Feng Y, et al. The role of sialyltransferases in gynecological malignant tumors[J]. Life Sci, 2020, 263: 118670.
doi: 10.1016/j.lfs.2020.118670
|
[20] |
Bhide GP, Colley KJ. Sialylation of N-glycans: mechanism, cellular compartmentalization and function[J]. Histochem Cell Biol, 2017, 147(2): 149-174.
doi: 10.1007/s00418-016-1520-x
pmid: 27975143
|
[21] |
Pietrobono S, Stecca B. Aberrant sialylation in cancer: biomarker and potential target for therapeutic intervention?[J]. Cancers, 2021, 13(9): 2014.
doi: 10.3390/cancers13092014
|
[22] |
Ou LL, He XZ, Liu NH, et al. Sialylation of FGFR1 by ST6Gal‑Ⅰ overexpression contributes to ovarian cancer cell migration and chemoresistance[J]. Mol Med Rep, 2020, 21(3): 1449-1460.
|
[23] |
Wang ZH, Geng ZH, Shao WW, et al. Cancer-derived sialylated IgG promotes tumor immune escape by binding to siglecs on effector T cells[J]. Cell Mol Immunol, 2020, 17(11): 1148-1162.
doi: 10.1038/s41423-019-0327-9
|
[24] |
Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases[J]. Cell Immunol, 2018, 333: 65-79.
doi: S0008-8749(18)30325-3
pmid: 30107893
|
[25] |
Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation[J]. Science, 2006, 313(5787): 670-673.
doi: 10.1126/science.1129594
pmid: 16888140
|
[26] |
Quast I, Keller CW, Maurer MA, et al. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity[J]. J Clin Invest, 2015, 125(11): 4160-4170.
doi: 10.1172/JCI82695
pmid: 26436649
|